***Joe Gantoss relies on knowing more, either through technical analysis & charts or DD & research.*** Thesis: GILD has been in a channel between ~87 and ~91. Joe already has Apr. GILD $100 calls. To finish in the money, Joe needs an 11% move upward in 28 days. The time decay on these options […]
March 17 Biotech Update
You are missing a lot of private interaction we are mostly using the private feed @CRGTrades to do so, the best way to be updated is to follow us through this link, please fill in all the info needed for easy confirmation! https://www.chimeraresearchgroup.com/twitter-page/ Well, I do not think we really learned anything new yesterday in […]
February 12 Biotech Update
The market remains crazy and the sector is filled with odd moves. Yesterday seemed to be a good day of outperformance for the large caps and today they are red while the market is green. There were some good movers in SMID yesterday and today but not a real rhyme or reason for who outperforms […]
February 11 Biotech Update
The markets remain in turmoil despite a nice start (but poor finish) yesterday. Interestingly it seemed yesterday at least that large cap biotech outperformed the broader market. Obviously it could very easily be an oversold bounce but in a world of limited earnings growth, one could make the case that some of the large cap […]
February 3 Biotech Update
The market remains tied to oil and while sentiment remains negative on oil it still has not made a new low. This is not to say that a new low is not coming but as long as it does not make a lower low, it is at least some positive for the market. Ultimately, we […]
February 1 Biotech Update
Different week but the same market. There remains a bias to the downside, although perhaps an optimist can see a slight outperformance of the sector. At the very least, it seems like the sector is not leading the market lower. We got some news this morning but the key this week will continue to be […]
GILD – Heavy Options Activity
Gilead Sciences Inc. (GILD) –Nasdaq GILD dropping hard after MRK receive the FDA approval for a less expensive alternative to Gilead’s hepatitis C drug and pricing it with more than 30% discount to the competitor drugs from Gilead and ABBV. We notices a huge Feb 19th call options activity, with over 25K of $89 Call […]
January 29 Biotech Update
It was obviously another bad day for the sector. The technicals look broken. The headlines are all about pricing. Buyers are on strike. There are no real exciting near term catalyst. Despite all of the negatives, there is some reason for hope at least over the medium term. 1. ISI had an impromptu call yesterday […]
January 7 Biotech Update
The year is off to an even worst start as all the secondaries are getting bad prices (to varying degrees of bad) and all are breaking those prices. China continues to collapse taking commodities with it as well as strengthening the dollar taking the markets with it. On the encouraging side, the technical analyst at […]
December 30 Biotech Update
Nothing newsworthy for the sector has happened in the past day. We had a nice rally the other day and perhaps that continues with a positive bias into the end of the year as investors and traders finish up the year but with volumes drying up it is really a toss-up how it will trade. […]
December 14 Biotech Update
We are once again in a macro world and the sector will be driven by it. Of course, even if we were not in a macro world the sector would likely still be underperforming as ASH did not inspire a lot of confidence and the sector offers a lot of chances for tax loss selling […]
November 25 Biotech Update
Trading is slow this week but news is not. Yesterday was better but I still think it is too early to call the sector back but at the very least I believe is has found its footing. Interestingly it seems that the SMID caps are outperforming the larger caps (finally) although they have a lot […]
October 28 Biotech Update
The sector seems to be getting its feet but unevenly and in fits and starts. It looks like the large caps are probably the most consistent outperformers with some strong SMID names but as a group it is much more mixed. We continue to be in earnings seasons and likely explains the outperformance of the […]
September 25 Biotech Update
The sector continues to get hit with the broader market. It feels like the sector is still facing the headwinds from the pricing discussions but as it fades into the background, the headwind will lift. Of course, it has to fade into the background and that remains an open question. My base case remains that […]
September 21 Biotech Update
Another slow news start to the week. The market background seems better but with a lack of real news/catalysts, the sector is likely we trade in line with market. It will be interesting to see how the sector trades with a lack of news as it may give us at least some sense as to […]
September 14 Biotech Update
Talk about a slow start to the week. Nothing really new, which probably means all eyes will remain on the Fed. I have no idea whether the Fed is going to raise rates or not or whether the market moves higher or lower if the rates are raised or not. In some ways, the best […]
September 11 Biotech Update
Macro seems to be slowly fading into the background but note that I said slowly as it will likely take more time and it should remain meaningful in the short term. Of course, fading into the background does not mean all is clear for the next move higher as I read the market as simply […]
August 10 Biotech Update
We are getting a spurt of IO collaborations this morning but no major news or M&A. After the sell off Friday (and come back), I would not be surprised to see that positive momentum continue this morning. Worst case scenario would be early strength and then faded all day. Best case, obviously, would be early […]
July 29 Biotech Update
The sector was a strong performer after the bell but it did not seem to last long. The sector should be strong given the bulk of the earnings but I cannot shake the feeling that sentiment has slipped. Perhaps it is the broader market acting as a drag but I am not convince the sector […]
July 27 Biotech Update
The market looks bad and it is bringing down the sector although I think BIIB has done a pretty good job at reversing some bullish biotech sentiment. That being said the sector might be outperforming the broader market a little as there was a nice big deal announced this morning. When all is said and […]
